tbuckley/cabot-search huggingface dataset:
Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges
Authors: Yang Yang, Xueting Deng, Quanpeng Li, Fei Wang, Lin Miao, Qi Jiang
Journal: Cancer Communications (2020)

Abstract Cholangiocarcinoma (CCA), a cancer with a relatively low incidence rate, is usually associated with poor prognosis. Current modalities for the diagnosis and treatment of CCA patients are still far from satisfactory. In recent years, numerous long noncoding RNAs (lncRNAs) have been identified as crucial players in the development of various cancers, including CCA. Abnormally expressed lncRNAs in CCA, regulated by some upstream molecules, significantly influence the biological behavior of tumor cells and are involved in tumor development through various mechanisms, including interactions with functional proteins, participation in competing for endogenous RNA (ceRNA) regulatory networks, activation of cancer‐related signaling pathways and epigenetic modification of gene expression. Furthermore, several lncRNAs are closely associated with the clinicopathological features of CCA patients, and are promising biomarkers for diagnosing and prognostication of CCA. Some of these lncRNAs play an important role in chemotherapy drug resistance. In addition, lncRNAs have also been shown to be involved in the inflammation microenvironment of CCA and malignant outcome of CCA risk factors, such as cholestatic liver diseases. In view of the difficulty of diagnosing CCA, more attention should be paid to detectable lncRNAs in the serum or bile. This review summarizes the recent knowledge on lncRNAs in CCA and provides a new outlook on the molecular mechanisms of CCA development from the perspective of lncRNAs. Moreover, we also discussed the limitations of the current studies and differential expression of lncRNAs in different types of CCA.
Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country
Authors: Antonio Adolfo Guerra Soares Brandão, Giancarlo Fatobene, Andre Abdo, Luis Alberto de Padua Covas Lage, Israel Bendit, Luciana Nardinelli, Sheila Aparecida Coelho de Siqueira, Debora Levy, Juliana Pereira, Eduardo M Rego, Vanderson Rocha
Journal: Blood (2020)
Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study
Authors: Rami S. Komrokji, Uwe Platzbecker, Pierre Fenaux, Guillermo Garcia-Manero, Ghulam J. Mufti, Valeria Santini, Maria Diez-Campelo, Carlo Finelli, Joseph G. Jurcic, Peter L. Greenberg, Mikkael A. Sekeres, Amer M. Zeidan, Amy E. DeZern, Michael R. Savona, Jeevan K. Shetty, Rodrigo Ito, George Zhang, Xianwei Ha, Daniel Sinsimer, Jay T. Backstrom, Amit Verma
Journal: Blood (2020)
Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model
Authors: Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Joshua Wiesner, Xiaona You, Yun Zhou, Terra Lasho, Mrinal M. Patnaik, Demin Wang, Robert Burns, Natalie S. Callander, Fotis Asimakopoulos, Jing Zhang
Journal: Blood (2020)
Abstract 488: Investigation of the Impact of Germ Line Variation in the K Channel Kcnj5 on the Renin-angiotensin Axis and Aldosterone Release in Human Subjects (linked)
Authors: Spoorthy Burli, James Goodman, Michalis Kostapanos, Kevin M O'Shaughnessy
Journal: Circulation Research (2020)

Introduction: Somatic mutations in the KCNJ5 potassium channel are found in significant number of patients with primary aldosteronism (PA). In a previous study, a rare non-synonymous E&gt;Q (E282Q) single nucleotide polymorphism (SNP) rs7102584 in the KCNJ5 channel was identified and an in vitro study confirmed its functionality. This study tested the hypothesis that this germline SNP would affect release of aldosterone and raise blood pressure (BP) under salt-loaded conditions. Methods: Healthy volunteers (30 Group A = SNP heterozygous carriers and 30 Group B = homozygous wild type, mean age: 59±11) were recruited through the UK BioResource, with equal gender distribution in the two groups (40% males, 60% females). Investigators were blinded to the genotype of each recruit. Volunteers were on a low salt diet (≤6 g/d) for a week, and then exposed to high oral salt intake (&gt;9 g/d) for a week. Clinic BP, 24hour ambulatory blood pressure measurements (ABPM), 24hour urine electrolytes, renal biochemistry, renin, aldosterone and renin aldosterone ratio (ARR), were measured before and after high salt exposure. Data were analysed using repeated measures ANOVA and adjusted for age. Results: Following salt loading, the mean day average systolic blood pressure (SBP) and diastolic blood pressure (DBP) rise on ABPM was 2.5 ± 1 mm Hg and 0.7± 0.7 mm Hg. Similarly, night-time average SBP and DBP rise was 2.2 ±1.2 mm Hg and 1.6 ± 0.9 mm Hg respectively. The ARR fell by a mean of 5.0 ±1.7 pmol/mU. There were no significant differences between carriers of the E/Q KCNJ5 variant and wild-type subjects in BP values and biochemical parameters at baseline or under salt-loading. Conclusions: This is the first study we are aware of, that has attempted in vivo translation of this KCNJ5 germline variant. The germline variation does not seem to drive hyperaldosteronism in vivo, although we cannot exclude this in the rare subjects who are homozygous for the variation (mean allele frequency approximately &lt;1 in 1000).
Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data
Authors: Osman Ilhan, Guldane Cengiz Seval, Ferit Avcu, Burhan Ferhanoglu, Güven Çetin, Erdal Kurtoglu, Figen Atalay, Emine Gulturk, Meliha Nalcaci, Meral Beksac
Journal: Blood (2020)
National Poison Center Calls Before vs After Availability of High-Dose Acetaminophen (Paracetamol) Tablets in Switzerland
Authors: Adrian Martinez-De la Torre, Stefan Weiler, Dominic Stefan Bräm, Samuel S. Allemann, Hugo Kupferschmidt, Andrea M. Burden
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Acetaminophen (paracetamol) is among the most widely used pain medications worldwide; while safe within the therapeutic range, intake exceeding 4000 mg/d can lead to hepatotoxicity. Prior evidence suggests that limiting the availability of large quantities of acetaminophen is associated with decreased acetaminophen-related poisonings and mortality; in Switzerland, 500-mg tablets are available over-the-counter (OTC) and, as of October 2003, 1000-mg tablets are available with prescription. <h3>Objective</h3> To evaluate the association of adding 1000-mg acetaminophen tablets to the Swiss market with utilization and poisonings. <h3>Design, Setting, and Participants</h3> This cross-sectional study used a quasi-experimental interrupted time series analysis to evaluate 15 790 acetaminophen poison records from January 1, 2000, to December 31, 2018. All calls for acetaminophen-related poisonings identified from the National Swiss Poisons Centre and all sales for oral acetaminophen tablets (prescription and OTC) dispensed between January 2000 and December 2018 were included. <h3>Exposure</h3> October 3, 2003 (Q4 2003), was defined as the intervention date, corresponding to the date of market entry for 1000-mg acetaminophen tablets in Switzerland. <h3>Main Outcomes and Measures</h3> The primary outcome was the number of quarterly acetaminophen-related poison calls to the National Poison Centre. Additional outcomes included quarterly sales for acetaminophen and change in poisoning circumstances, stratified by preintervention and postintervention periods and by formulation (ie, 500-mg and 1000-mg tablets). <h3>Results</h3> Between 2000 and 2018, 15 790 acetaminophen-related poisoning calls were identified, of which 10 628 (67.3%) were regarding women, and the mean (SD) age of patients was 25.2 (18.2) years. The interrupted time series analysis identified a significant increase in the slope for the number of reported poisonings following the intervention point, particularly for accidental circumstances (<i>z </i>score, −3.62;<i>P</i> &lt; .001). In the preintervention period, 120 of 961 poisonings (15.3%) involved a dose greater than 10 000 mg, while for the postintervention period, 1140 of 5696 (30.6%) had a dose larger than 10 000 mg (<i>P</i> &lt; .001). There was a rapid uptake in 1000-mg acetaminophen sales, while sales of the 500-mg tablet decreased slightly. Since 2012, a mean (SD) of 20.7 million (1.4 million) 1000-mg tablets were dispensed quarterly compared with 2.7 million (0.5 million) 500-mg tablets. <h3>Conclusions and Relevance</h3> This study found a significant increase in acetaminophen dispensing and acetaminophen-related poisonings in Switzerland following the approval of 1000-mg tablets in 2003. The availability of 1000-mg acetaminophen should be re-evaluated to minimize the potential for accidental poisonings.
Developing Human Skin Contains Lymphocytes Demonstrating a Memory Signature
Authors: Miqdad O. Dhariwala, Dhuvarakesh Karthikeyan, Kimberly S. Vasquez, Sepideh Farhat, Antonin Weckel, Keyon Taravati, Elizabeth G. Leitner, Sean Clancy, Mariela Pauli, Merisa L. Piper, Jarish N. Cohen, Judith F. Ashouri, Margaret M. Lowe, Michael D. Rosenblum, Tiffany C. Scharschmidt
Journal: Cell Reports Medicine (2020)

Lymphocytes in barrier tissues play critical roles in host defense and homeostasis. These cells take up residence in tissues during defined developmental windows, when they may demonstrate distinct phenotypes and functions. Here, we utilized mass and flow cytometry to elucidate early features of human skin immunity. Although most conventional αβ T (Tconv) cells in fetal skin have a naive, proliferative phenotype, a subset of CD4+ Tconv and CD8+ cells demonstrate memory-like features and a propensity for interferon (IFN)γ production. Skin regulatory T cells dynamically accumulate over the second trimester in temporal and regional association with hair follicle development. These fetal skin regulatory T cells (Tregs) demonstrate an effector memory phenotype while differing from their adult counterparts in expression of key effector molecules. Thus, we identify features of prenatal skin lymphocytes that may have key implications for understanding antigen and allergen encounters in utero and in infancy.
LSD1 Inhibition with IMG7289 (bomedemstat) Rebalances Megakaryopoiesis and Erythropoiesis in a Patient with MPN/MDS with Refractory Anemia with Ringed Sideroblast and Marked Thrombocytosis with JAK2 and SF3B1 Mutations
Authors: Abdulraheem Yacoub, Hugh Young Rienhoff
Journal: Blood (2020)
Abstract PO-132: CaTCH - A barcode-guided CRISPRa-inducible reporter to isolate clones from heterogeneous populations
Authors: Christian Umkehrer, Felix Holstein, Laura Formenti, Julian Jude, Kimon Froussios, Tobias Neumann, Shona M. Cronin, Lisa Haas, Jesse Lipp, Thomas R. Burkard, Michaela Fellner, Thomas Wiesner, Johannes Zuber, Anna C. Obenauf
Journal: Cancer Research (2020)

Abstract The emergence of resistant cell clones to targeted therapies poses a significant issue in the treatment of metastatic melanoma. While these founding clones are often extremely rare in a starting population, their isolation and characterization holds unique potential for understanding disease processes, uncovering novel biomarkers and developing therapeutic concepts. The functional characterization of such founder clones and comprehensive comparisons to their post-selection counterparts requires live cells. To achieve this, we developed a novel lineage tracing tool termed CaTCH (CRISPRa tracing of clones in heterogeneous cell populations). CaTCH combines precise mapping of the lineage history of millions of cells with the ability to isolate any given clone alive from a complex population based on genetic barcodes. CaTCH thereby enables the retrospective isolation and analysis of founding clones from heterogeneous cell populations prior to evolutionary selection. In first applications, we use CaTCH to provide insights into the development of resistance to targeted cancer therapies. We demonstrate that CaTCH can be used to trace and isolate a single pre-existing therapy-resistant clone from a complex cancer cell population in vitro. Furthermore, we validate the utility of CaTCH for applications in vivo by investigating the origins of resistance to clinically relevant RAF/MEK inhibition in an immunocompetent melanoma mouse model. Here we find that most clones have the capacity to acquire resistance to combined RAF/MEK inhibitor therapy, indicating that resistance to this clinically relevant regimen is a universally achievable state in this model. We envision that CaTCH will address fundamental questions in basic and translational research (e.g., how cell identity states and trajectories are determined in therapy resistance, metastasis formation, tissue development and somatic cell re-programming), potentially revealing new vulnerabilities that can serve as targets for therapies. Citation Format: Christian Umkehrer, Felix Holstein, Laura Formenti, Julian Jude, Kimon Froussios, Tobias Neumann, Shona M. Cronin, Lisa Haas, Jesse Lipp, Thomas R. Burkard, Michaela Fellner, Thomas Wiesner, Johannes Zuber, Anna C. Obenauf. CaTCH - A barcode-guided CRISPRa-inducible reporter to isolate clones from heterogeneous populations [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-132.
Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia
Authors: Sunisa Kongkiatkamon, Yasunobu Nagata, Vera Adema, Hassan Awada, Misam Zawit, Laila Terkawi, Simona Pagliuca, Carmelo Gurnari, Cassandra M Kerr, Mikkael A. Sekeres, Hetty E. Carraway, Yogenthiran Saunthararajah, Bhumika J. Patel, Jaroslaw P. Maciejewski, Valeria Visconte
Journal: Blood (2020)
Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity
Authors: Chiara F Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Chiara Buracchi, Gian Maria Borleri, Silvia Zaninelli, Giuliana Rizzuto, Sarah Tettamanti, Valentina Colombo, Giovanni Cazzaniga, Benedetta Cabiati, Attilio Rovelli, Ettore Biagi, Stefania Galimberti, Fabrizio Benedicenti, Eugenio Montini, Silvia Ferrari, Martino Introna, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi
Journal: Blood (2020)
Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group
Authors: Giulia Maggioni, Cristina Astrid Tentori, Maria Teresa Voso, Sonja Heibl, Klaus H. Metzeler, Jan Moritz Middeke, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, Alfonso Piciocchi, Annika Maria Dufour, Jordi Esteve, Marta Pratcorona, Valentina Mancini, Federico Lussana, Karsten Spiekermann, Christian Thiede, Friedrich Stolzel, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, David Gallardo, Susana Vives, Olga Salamero, Elisabetta Todisco, Claudia Basilico, Francesco Passamonti, Sigrid Machherndl-Spandl, Lisa Pleyer, Jorge Sierra, Francesc Solé, Matteo Giovanni Della Porta
Journal: Blood (2020)
The Natural History of <i>NPM1</i>MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)
Authors: Ing Soo Tiong, Richard Dillon, Adam Ivey, Chung Hoow Kok, James Anton Kuzich, Nisha Thiagarajah, Ashish Bajel, Nicola Potter, Matthew Smith, Claire Hemmaway, Abin Thomas, Amanda Gilkes, Nigel H. Russell, Andrew H. Wei
Journal: Blood (2020)
Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Madiha Iqbal, Yennifer Gil, Jonas Paludo, Allison C. Rosenthal, Zhou Li, Manuel Beltran, David J. Inwards, Luis F. Porrata, Ivana Micallef, Jose C Villasboas, Patrick B. Johnston, Stephen M. Ansell, Craig B. Reeder, Hemant S. Murthy, Vivek Roy, James M. Foran, Han W. Tun, Mohamed A. Kharfan-Dabaja, Ernesto Ayala
Journal: Blood (2020)
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis
Authors: Teodora Doherty, Ella J. Daly, Janice Miller, Vanina Popova, M. Soledad Cepeda, Wayne C. Drevets, Carla M. Canuso
Journal: Psychotherapy and Psychosomatics (2020)
Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
Authors: Danielle Hammond, Sanam Loghavi, Marina Konopleva, Tapan M. Kadia, Naval Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood (2020)
Daratumumab and Venetoclax-Containing Regimens in the Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies
Authors: Fan Yang, Zhihui Li, Changwei Dong, Yang LEI, YanPing Geng, XiaoPei Wen, Yan Zhou, Tong Wu
Journal: Blood (2020)
Immunoadsorption, Intravenous Immunoglobulins and Rituximab (IIR): Successful New Treatment Approach for Severe Anti K- Alloimmunisation during Pregnancy
Authors: Annina Capraru, Luigi Raio, Martin Müller, Michael Daskalakis, Alicia Rovo, Hustinx Christian Henri, McDougall Jane, Sacha Sergio Zeerleder, Behrouz Teleghani Mansouri
Journal: Blood (2020)
SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia
Authors: Stephane De Botton, Thomas Cluzeau, Carlos Enrique Vigil, Rachel J. Cook, Philippe Rousselot, David A Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Michael R. Savona, Don Park, Michael J. Kelly, Angela Volkert, Li Zhou, Qing Kang-Fortner, David A. Roth, Eytan M. Stein
Journal: Blood (2020)
COVID-19 Transmission Conclusions Justified by the Analysis Results?—Reply
Authors: Hao-Yuan Cheng, Ta-Chou Ng, Hsien-Ho Lin
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That <i>DNMT3A</i> R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation
Authors: Anna S Nam, Neville Dusaj, Franco Izzo, Rekha Murali, Tarek H Mouhieddine, Robert M Myers, Jesus Sotelo, Salima Benbarche, Federico Gaiti, Sabrin Tahri, Omar Abdel-Wahab, Irene M. Ghobrial, Ronan Chaligne, Dan A. Landau
Journal: Blood (2020)
Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia
Authors: Paula A. Lengerke Diaz, Michael Y. Choi, Eider F. Moreno Cortes, Jose V. Forero, Juliana Velez-Lujan, Carlos I. Amaya-Chanaga, Thomas Kipps, Januario E. Castro
Journal: Blood (2020)
Abstract 11795: Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension -High-throughput Screening of 5,562 Compounds-
Authors: Ryo Kurosawa, Kimio Satoh, Nobuhiro Kikuchi, Taijyu Satoh, Junichi Omura, Masamichi Nogi, Shinichiro Sunamura, Mohammad Abdul Hai Siddique, M. Elias Al-Mamun, Nobuhiro Yaoita, Toru Shimizu, Hiroaki Shimokawa
Journal: Circulation (2019)

Introduction: Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation of pulmonary artery smooth muscle cells (PASMCs) accompanying increased production of inflammatory fac...
Extracorporeal life support for adults with acute respiratory distress syndrome
Authors: Alain Combes, Matthieu Schmidt, Carol L. Hodgson, Eddy Fan, Niall D. Ferguson, John F. Fraser, Samir Jaber, Antonio Pesenti, Marco Ranieri, Kathryn Rowan, Kiran Shekar, Arthur S. Slutsky, Daniel Brodie
Journal: Intensive Care Medicine (2020)
Abstract 353: High Density Lipoprotein Regulates Tumor Necrosis Factor Alpha and Jun Kinase Signaling Pathway in Adipocytes
Authors: Qiaoqing Zhong
Journal: Circulation Research (2020)

Background: High-density lipoproteins (HDL) is presumed to exhibit cardiovascular protection, since HDL mediate the reverse transport of cholesterol and exhibit strong anti-inflammatory potential. Previous studies have found that HDL can reduce the level of IL-8 secreted by the inflammatory adipocytes, as well as affect the expression of adiponectin and tumor necrosis factor-alpha (TNF-α) under the inflammatory condition in adipocytes. These studies indicate that HDL is closely related to the inflammatory response of adipose tissue, yet its mechanism has not been fully understood. Secretory leucocyte protease inhibitor (SLPI), a nonglycosylated single-chain polypeptide protein, may play an important role in diet-induced obesity and adipocyte inflammation. Purpose: To study the role of SLPI in HDL anti-inflammatory action in the adipocytes, and explore the mechanism of the action. Methods: 3T3-L1 Adipocytes were induced to differentiation and maturation by culturing. Acute inflammation in adipocytes was induced by LPS (100 ng/ml, 6h), and then the adipocytes were pretreated with HDL and/or SLPI-siRNA. The protein and mRNA levels of SLPI, TNF-α and JNK were examined by Western blotting and qRT-PCR assay, respectively. In addition, the levels of inflammatory factors were measured by ELISA. Results: HDL up-regulated SLPI expression, down-regulated TNF-α expression, and inhibited the secretion of inflammatory factors such as IL-1, IL-6, IL-8 and MCP-1 in 3T3-L1 Adipocytes pre-treated by LPS. Silencing of SLPI by its siRNA effectively abolished the anti-inflammatory effect of HDL. JNK inhibitor (SP600125) partially restored the anti-inflammatory effects of HDL decreased by SLPI knockdown and decreased the secretion of inflammatory factors. Conclusions: These data suggest that HDL up-regulate the expression of SLPI and inhibit the inflammation in 3T3-L1 Adipocytes pre-treated by LPS. The anti-inflammatory effect of HDL, including inhibition of the secretion of inflammatory factors via TNF-α/JNK signaling pathway, probably viat up-regulating the SLPI expression. Key words: high-density lipoprotein, Inflammation, Adipocytes